A recent Australian study highlights the need for a new generation of effective inhalable medications for patients with asthma and other lung diseases.

Mehra Haghi, pharmaceutical scientist, hopes to further a platform through which a wide range of drugs can be delivered by inhalation; this would include antibiotics utilized to treat tuberculosis and anti-inflammatory drugs to address asthma and chronic obstructive pulmonary disease (COPD).

Several currently used respiratory treatments have to be injected or swallowed as pills since researchers have not yet been able to fabricate them into suitable inhalable products, explained study author Haghi, who is a lecturer in the Graduate School of Health at the University of Technology Sydney (UTS).

“Formulating treatment for inhalation is more challenging because the formulated micro-particles need to be the right size to travel all the way down to the lung without causing sensitivity,” she explained. The researcher recently joined a prestigious Humboldt Research Fellowship in Germany and will dedicate four months exploring a unique, new testing model.

View the full story at www.lungdiseasenews.com